Abstract
Being short is a natural diversity of the human race. In 2003, the Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of idiopathic short stature (ISS) in children. Research has shown that GH therapy in children with ISS has a variable effect on increasing height. However, the literature has not shown the efficacy in improving psychosocial function to justify the costs and potential adverse effects. GH use in children with ISS is a subject of great ethical debate. Ethical implications including beneficence, nonmaleficence, autonomy, and justice are discussed. ISS requires thoughtful consideration by the patient, parents, and healthcare professionals. Well-designed long-term studies are needed to determine the benefits of such treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
